Dr. McCreary is a neuropsychopharmacologist, with a recognized track record in drug discovery of novel antiparkinsonian and antipsychotic agents. He has strong industrial experience and is currently neurochemistry and pharmacokinetics Project Leader.
Collaboration: action of serotonin 5-HT1A agonists in models of Parkinson’s disease
https://neurolixis-com.mon.world/nl.linkedin.com/pub/andrew-mccreary/4/440/805
